Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.36 |
| ▸ | CCR2 | P41597 | 7/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21384586 | 0.90 | CNR2 (0.37) | CNR2CCR2BRAFCNR1CYP11B1 | |
| SCHEMBL21394400 | 0.83 | MRGPRX1 (0.44) | SCN5ASCN9AMRGPRX1 | |
| SCHEMBL21394421 | 0.75 | MRGPRX1 (0.46) | MRGPRX1 | |
| SCHEMBL21384571 | 0.71 | MRGPRX1 (0.60) | MRGPRX1 | |
| SCHEMBL21384560 | 0.66 | MCL1 (0.46) | CNR2CCR2CNR1MRGPRX1 | |
| SCHEMBL21384575 | 0.66 | MCL1 (0.46) | CNR2CCR2CNR1MRGPRX1 | |
| SCHEMBL392514 | 0.65 | MAP2K1 (0.43) | CNR2BRAFCNR1MRGPRX1 | |
| SCHEMBL21384613 | 0.65 | MRGPRX1 (0.61) | MRGPRX1 | |
| SCHEMBL393515 | 0.65 | BRAF (0.40) | CNR2CCR2BRAFCNR1EPHX2 | |
| SCHEMBL21384561 | 0.64 | ACLY (0.48) | SCN5ASCN9AMRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019179436-A1 | ACID AMIDE COMPOUND AND USE THEREOF IN TREATMENT OF CANCERS | 成都海创药业有限公司 | 2019-09-26 | — | — | WO | disclosed |